Copaxone, Teva

Copaxone (glatiramer acetate)
Multiple Sclerosis
Teva Pharmaceutical Industries
Global Sales 2012: $3.996 billion
U.S. Sales 2012: $2.9 billion
Expiration Date: May 2014

Like other drugmakers facing major patent losses, Teva ($TEVA) has been working for years to prepare for Copaxone's ride into the sunset. The company made a string of deals in 2010 and 2011, including its purchase of Cephalon, the U.S.-based maker of narcolepsy treatments Nuvigil and Provigil, and the cancer drug Treanda. Before those deals, Copaxone accounted for two-thirds of the company's specialty pharma sales and almost one-fifth of sales overall. And even last year, Copaxone made up a good chunk of the company's growth, with an increase of 12%.

For 2013, the Copaxone story could be more mixed. In addition to competition from Novartis' ($NVS) new oral treatment Gilenya, Copaxone has to deal with Biogen Idec's ($BIIB) Tecfidera, another pill that has hit the ground at a sprint. After 17% growth in the first quarter of 2013, Copaxone sales grew by just 9% for the second quarter, when Tecfidera was launched. Whether that trend continues into the third quarter remains to be seen, of course.

It also remains to be seen--as Teva is happy to point out--whether a generic version of the drug will actually hit the market when the May 2014 patent expires. Teva says Copaxone is tough to copy, and it doesn't think a generics rival could move quickly enough to launch by then. But U.S.-based Mylan ($MYL), which first challenged the Copaxone patent, says it will be ready and waiting. Meanwhile, CEO Jeremy Levin isn't taking chances; the company's cost-cutting program just grew to $2 billion, with 5,000 jobs on the block.

For more:
Special Report: Top 20 Orphan Drugs by 2018 - Copaxone
Teva plots 5,000 more job cuts in $2B savings drive
U.S. court upturns Teva's patents on cash-cow Copaxone
Amid $2B in cost-cutting, Teva's sales suffer from generic erosion
Levin lays out 4-year plan to turn Teva into a brand

-- Tracy Staton (email | Twitter)

Copaxone, Teva
Read more on

Suggested Articles

Manufacturing issues have caused GlaxoSmithKline to halt production and distribution of Excedrin, which has led to outages at some pharmacies.

Drug pricing remains the pharma industry's top concern in 2020, execs said in a survey, as political threats continue from Washington, D.C.

Allergan updated its Botox marketing for chronic migraine by featuring strong women powering through their too-frequent migraine days.